Oncogenic Driver Mutations and Signaling Pathways in Tumorigenesis and Therapy in Lung Cancer

Dear Colleagues,

Lung cancer poses a significant global health challenge as its incidence and mortality rates continue to rise. The initiation, progression, and response to therapy for lung cancer are heavily influenced by oncogenic driver mutations and dysregulated signaling pathways. This Special Issue, titled “Oncogenic Driver Mutations and Signaling Pathways in Tumorigenesis and Therapy in Lung Cancer”, aims to delve into the complex landscape of oncogenic drivers and signaling cascades involved in lung tumorigenesis and treatment. By uncovering the molecular mechanisms behind cancer progression, our goal is to pinpoint therapeutic targets and propel precision medicine approaches to improve patient outcomes.

Contributions to this Special Issue should encompass various research methodologies, including, but not limited to, the following:

1. Genomic Studies: Exploring the genomic profile of lung cancer through techniques such as whole-genome sequencing, exome sequencing, and single-cell sequencing to uncover novel oncogenic driver mutations and genetic changes.
2. Preclinical Models: Utilizing animal models, patient-derived xenografts (PDX), organoids, and in vitro cell cultures to understand the functional impact of oncogenic driver mutations and signaling pathway disruptions in lung tumorigenesis. This includes models that involve manipulating oncogenic driver mutations to study tumorigenesis and treatment response.
3. Molecular Mechanisms: Investigating the molecular processes that drive the activation of oncogenic signaling pathways, the interplay between different pathways, and the influence of tumor microenvironment components on lung cancer progression.
4. Therapeutic Strategies: Exploring new therapeutic avenues that target oncogenic drivers and signaling pathways in lung cancer, such as small molecule inhibitors, immunotherapy, gene therapy, and combination treatments.
5. Biomarker Discovery: Identifying and validating biomarkers that can predict treatment response, disease prognosis, and patient categorization in lung cancer, including circulating tumor DNA (ctDNA), RNA expression profiles, and imaging biomarkers.
6. Resistance Mechanisms: Studying the mechanisms underlying acquired resistance to targeted therapies and immunotherapy in lung cancer, with a focus on developing strategies to overcome resistance and enhance treatment outcomes.

Authors are encouraged to submit original research articles, reviews, and meta-analyses that advance our knowledge of oncogenic driver mutations and signaling pathways in lung cancer, specifically focusing on tumorigenesis and treatment strategies. Studies involving the manipulation of oncogenic driver mutations in animal models to investigate tumorigenesis and treatment responses are particularly welcome.

Dr. Lei Duan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• lung cancer
• oncogenic driver mutations
• signaling pathways
• tumorigenesis
• therapy
• precision medicine
• targeted therapy
• biomarkers
• resistance mechanisms
• therapeutic strategies